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The concept of thresholds in genotoxicity has been open for
debate in the last decades. The micronucleus (MN) test
contributed to a large extent in understanding the dose–
response relationship for aneugens and clastogens. The
threshold concept for aneuploidy is well accepted by the
scientific community based on the data and for mechanistic
reasons. The concept of threshold for clastogens is still
challenging. Acceptance is based on a case-by-case basis
together with thorough mechanistic understanding of the
different steps from the mutagen–target interactions to
MN formation for this class of genotoxicants. This review
summarises the significant achievements in the assessment
of threshold for genotoxins using the MN test and
concludes with an overview of knowledge gaps and
recommendations.
Introduction
The micronucleus (MN) test has been extensively used in
a variety of exploratory and mechanistic investigations with the
aim to understand the basic mechanisms underlying genotox-
icity. The simplicity and the readiness to be applied to a variety
of cell types either in vitro or in vivo made it a versatile tool
that contributed to a large extent in our understanding of key
toxicological issues related to genotoxins and their effects at
the cellular and organism levels. Recently, the final acceptance
of the in vitro MN test Organisation for Economic Co-
operation and Development (OECD) guideline 487 (1) together
with the standard in vivo MN test OECD guideline 474 (2) will
position the assay to become a key driver in the determination
of the genotoxicity potential in exploratory research as well as
in the regulatory environment. In this manuscript, we review
the major achievements using the MN test in understanding the
dose–response relationship of genotoxicants and specifically
the non-linear dose–effect relationship where the threshold
mode of action (MOA) is expected or demonstrated. It is
widely accepted that indirect-acting genotoxicants may show
a threshold MOA and exhibit a level of exposure below which
no genotoxic effect may be observed. Among these thresholded
MOA one may mention aneuploidy, high level of cytotoxicity,
inhibition of protein/DNA synthesis and ionic imbalance (3).
For some mechanisms, a threshold is expected, although hard
to prove (4). On the contrary, chemicals which directly react
with DNA are expected to induce mutation as a result of
a single reaction of the compound with the DNA and therefore
exhibit a non-threshold response (5–9). However, this
hypothesis does not take into account the cellular protective
mechanisms of the exposed cell or organism (9,10). Cytopro-
tective mechanisms such as DNA repair or detoxification
should be considered when the threshold is determined.
Significant achievements
Aneugens
Aneugens may act on non-DNA targets such as the inhibition
of spindle function with no direct interaction with DNA and it
is assumed that a critical number of target sites must be
occupied before the biological effect occurs and therefore these
mechanisms may have a threshold (11). Therefore, the risk for
adverse effects following human exposure to an aneugen could
be minimal, if the threshold of activity has been clearly
demonstrated in vivo and in vitro (Table I) and providing the
human exposure level is below this threshold. Spindle poisons
have been used as model compounds to demonstrate existence
of thresholds for aneuploidy induction. Multiple interactions of
spindle poisons with the tubulin molecule are necessary to disturb
microtubule dynamics and affect chromosome segregation
leading to aneuploidy and therefore a threshold dose–response
relationship is expected.
In studies by Elhajouji et al. (12,13), a threshold effect for
chromosome loss and chromosome non-disjunction have been
determined in vitro in human lymphocytes for spindle poisons
such as colchicine, carbendazim, nocodazole and mebendazole.
Flow cytometry sorting and further fluorescence in situ
hybridization (FISH) analysis with pancentromeric DNA probes
was performed to distinguish between centromere-positive
(MNCenþ) versus centromere-negative (MNCen) MN. The
cytokinesis-block MN assay, in combination with centromeric
probes for chromosomes 1 and 17, was used to identify non-
disjunction. The non-disjunction threshold values for colchi-
cine, carbendazim, nocodazole and mebendazole were 0.020,
1.046, 0.033 and 0.135 lM, respectively, while those for
chromosome loss were 0.037, 2.61, 0.066 and 0.271 lM,
respectively. Elhajouji et al. (12) investigated in vitro MN in
human lymphocytes with a discontinuous regression model
which reflected a ‘jump’ in the regression line for the possible
threshold evaluation. A piecewise linear regression or break-
point model was fitted to the centromere positive versus
centromere-negative cells. In the second paper, Elhajouji et al.
(13) defined a threshold in two ways; firstly, as the point where
a statistically non-significant increase (last statistically non-
significant concentration) changes to a statistically significant
increase (first statistically significant concentration) and sec-
ondly, by estimating inflection points (the point where there is
a change from concavity to convexity of a curve) using
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a polynomial model as an approximate determination of
a threshold. These authors have also demonstrated that the
threshold for non-disjunction is lower than that for chromosome
loss. This finding is to be expected since less damage to
microtubules is needed to induce a mono-oriented chromosome
(one kinetochore captured by microtubules) than to induce
chromosome loss where none of the kinetochores are captured
by microtubules. A study by Bentley et al. (15) was conducted
to determine a threshold mechanism of action for benomyl and
carbendazim-induced aneuploidy in vitro. Using binucleate
human lymphocytes and FISH technique, the authors were able
to characterise a threshold mechanism of action for the two
spindle inhibitors. Induction of chromosome non-disjunction,
chromosome loss and gain and polyploidy were evaluated for
six different chromosomes (1 and 8, 11 and 18 and X and 17) in
interphase nuclei. The threshold response was nearly identical
among the six analyzed chromosomes for both benomyl and
carbendazim. The concentrations at which statistically signifi-
cant increases in non-disjunction first appeared ranged from 3.8
to 4.1 mM for benomyl and from 3.2 to 4.3 mM for
carbendazim. Threshold concentrations were also determined
for chromosome loss (benomyl and carbendazim) and for
MNCenþ for benomyl only. These were found to be equal to
or, in most cases, greater than the threshold concentrations for
non-disjunction (15). Potential thresholds have also been
established for spindle poisons nitrobenzene and benzonitrile.
MN induction by these test compounds in V79 cells, as well as
effects on the formation and stability of microtubules and on
motor protein functions was studied by Bonacker et al. (17).
The observed data clearly demonstrate a chromosomal end
point of genotoxicity, expressed as aneugenic effects, for both
nitrobenzene and benzonitrile at remarkably low concentrations,
with a lowest-effect concentration at 0.01 lM and no-effect
concentrations between 0.001 and 0.005 lM.
In a study by Steiblen et al. (16), the threshold levels for
nocodazole and paclitaxel were identified using the comparison
of the in vitro MN assay in human lymphocytes and mouse
splenocytes. For nocodazole, a no observed effect level
(NOEL) has been identified as 50 nM in both human
lymphocytes and mouse splenocytes. The results were
comparable with those reported by Elhajouji et al. (13), who
found that under the same experimental conditions, the NOEL
of nocodazole was 33 nM in human lymphocytes. For
paclitaxel, the NOEL was 0.5 nM in mouse splenocytes, while
it was 2.5 nM in human lymphocytes, which indicates a higher
degree of sensitivity of the mouse splenocyte compared with
the human lymphocyte in this case (16).
Recent studies by Johnson and Parry (18) have demonstrated
that the plastics component bisphenol-A (BPA) and the natural
pesticide rotenone, both known as spindle poisons, induce MN
and modify the functioning of the microtubule organising
centres of the mitotic spindles of cultured mammalian cells in
a dose-dependent manner. The cytokinesis-blocked MN assay
in human lymphoblastoid cell lines AHH-1 and MCL-5 and in
Chinese hamster V79 cell lines was used for these studies. For
a mechanistic evaluation of the aneugenic effects of BPA and
rotenone, fluorescently labelled antibodies were used to
visualise microtubules (alpha-tubulin) and microtubule organ-
ising centres (gamma-tubulin). A NOEL at 10.8 lg/ml BPA
was observed for MN induction. Rotenone showed a small
increase in MN induction with the first significant effect at 0.25
ng/ml in V79 cells but there was no significant effect in the
metabolically competent cell line, MCL-5. The NOELs for
tripolar mitotic spindle induction in V79 cells were 7 lg/ml for
BPA and 80 pg/ml for rotenone (18).
The existence of such thresholds in vitro is regarded as
evidence for the existence of a safety margin; however, this
cannot be used directly for risk evaluation in humans. It is not
known how concentrations found in vitro in a particular type of
cells, e.g. lymphocytes, can be extrapolated to somatic and/or
germ cells in vivo and further investigations are therefore
required (3). Evaluation of the biological threshold for
Table I. Overview of the NOEL values for aneugenic compounds based on literature data and discussed in this review
Compound CAS number Mechanism In vitro/in vivo Cell system NOEL value References
Colchicine 64-86-8 Spindle poison In vitro Human lymphocytes n.d. 0.020 lM, ch.l 0.037 lM (12,13)
In vivo MN in mouse peripheral blood 0.49 mg/kg (14)
Carbendazim 10605-21-7 Spindle poison In vitro Human lymphocytes n.d. 1.046 lM, ch.l 2.61 lM (12,13)
In vitro Human lymphocytes 3.2–4.3 mM (15)
In vivo MN in mouse bone marrow 66 mg/kg
In vivo MN in mouse bone marrow 8 lg/ml
Nocodazole 31430-18-9 Spindle poison In vitro Human lymphocytes n.d. 0.033 lM, ch.l 0.066 lM (12,13)
Spindle poison In vitro Human lymphocytes and mouse
splenocyes
50 nM (16)
Mebendazole 31431-39-7 Spindle poison In vitro Human lymphocytes n.d. 0.135 lM, ch.l 0.271 lM (12,13)
Benomyl 17804-35-2 Spindle poison In vitro Human lymphocytes 3.8–4.1 mM (15)





Spindle poison In vitro MN induction in V79 cells 0.001–0.005 lM (17)
Paclitaxel 33069-62-4 Spindle poison In vitro Human lymphocytes 2.5 nM (16)
In vitro Mouse splenocytes 0.5 nM (16)
Bisphenol-A 80-05-7 Spindle poison In vitro MN assay in AHH-1, MCL-5 and
V79 cell lines; tripolar mitotic
10.8 lg/ml (18)
spindle induction in V79 cells 7 lg/ml
Rotenone 83-79-4 Spindle poison In vitro MN assay in V79 cell line 0.25 ng/ml (18)
Spindle induction in V79 cells 80 pg/ml
Vincristine 57-22-7 Spindle poison In vivo MN in mouse bone marrow 0.01 mg/kg (19)
In vivo MN in mouse peripheral blood 0.017 mg/kg (14)
Vinblastine 865-21-4 Spindle poison In vivo MN in mouse peripheral blood 0.35 mg/kg (14)
n.d., non-disjunction; ch.l, chromosome loss.
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induction of non- maturing, naked mouse oocytes and in vitro
cultured human lymphocytes exposed to nocodazole suggest
that isolated in vitro maturing oocytes are not more sensitive to
classic aneugens such as nocodazole when compared to
mitotically dividing cells, despite the differences in spindle
formation and cell cycle regulation (3,20).
Some experimental data with aneugens in vivo were
published by Seiler et al. (21). In this study, micronucleated
erythrocytes, induced by carbendazim, were investigated in
mouse bone marrow. Carbendazim was found to inhibit tubulin
association at the concentration of 10 lg/ml (100 mg/kg) and,
thus, it was concluded that the threshold concentration was 8
lg/ml. This data is supported by the study of Bentley et al. (15)
where NOEL for benomyl was demonstrated at 100 and 66 mg/
kg for carbendazim. In experiments by Tinwel and Ashby (19),
the minimal detectable level for vincristine was demonstrated
in mouse bone marrow at a dose of 0.01 mg/kg. In a study by
Asano et al. (22), authors showed that a non-linear dose–
response relationship exists for the spindle poison colchicine.
A recent study by Cammerer et al. (14), with the aneugens
vinblastine, vincristine and colchicine, demonstrates a non-
linear dose–response relationship, clearly indicating the
presence of a threshold dose for all tested compounds. Studies
were performed in mouse peripheral blood after single
administration of the test compound. The last not statistically
significant and the first statistically significant concentrations
were identified with the Dunnett’s test. Further, assuming that
in case of a non-linear dose response, the threshold
concentration will be situated between these points; the linear
regression analysis was performed independently with the set
of data lower than the first statistically significant concentration
and higher than the last statistically non-significant concentra-
tion. In a next step, the determination of the intersection point
for both regression lines was performed and the obtained
concentration was considered as a threshold. Based on the
mathematical modelling performed, the threshold level for
aneuploidy induction is 0.35 mg/kg for vinblastine, 0.017 mg/
kg for vincristine and 0.49 mg/kg for colchicine (14). As
summarised in Table I the available literature data clearly
indicate the presence of threshold dose–response relationships
for aneugens that target microtubules.
Clastogens
Table II provides an overview of the clastogens discussed in
this review and includes the NOEL values as estimated in the
respective publications.
Ionising radiation. Ionising radiation induces DNA damage
by direct interaction with DNA or via reactive oxygen
species (ROS). It has been reported that low-dose radiation
Table II. Overview of the NOEL values for clastogenic compounds based on literature data and discussed in this review
Compound CAS Number Mechanism In vitro/
in vivo
Cell system NOEL value References
X-rays — Ionizing radiation In vivo Bone marrow/CBS/lac male mice/
Chronic 0.07 mGy/h
35–61 cGy (23)
Genistein 446-72-0 Topoisomerase II inhibition In vitro Mouse splenocytes 12.5 lM (24)
L5178Y mouse lymphoma cell line 0.5 lg/ml (8)
Ciprofloxacine 85721-33-1 Topoisomerase II inhibition In vitro L5178Y mouse lymphoma cell line 25 lg/ml (8)
Etoposide 33419-42-0 Topoisomerase II inhibition In vitro L5178Y mouse lymphoma cell line 0.005 lg/ml (8)
Doxorubicin 25316-40-9 Topoisomerase II inhibition In vitro L5178Y mouse lymphoma cell line 0.002 lg/ml (8)
Potassium bromate 7758-01-2 ROS inducer In vitro TK6 human lymphoblastoid cell line/
1-h treatment
0.9 mM (4)
TK6 human lymphoblastoid cell line/
2-h treatment
0.2 mM
TK6 human lymphoblastoid cell line/
3-h treatment
5.05 mM
TK6 human lymphoblastoid cell line/
24-h continuous treatment
0.025 mM
Glucose oxidase 9001-37-0 Oxidation of beta-D-glucose
to produce gluconic acid
and H2O2
In vitro TK6 human lymphoblastoid cell line/
1-h treatment
1.8 10-5 U/ml (4)
Bleomycin 9041-93-4 ROS inducer In vitro TK6 human lymphoblastoid cell line/
1 h treatment
0.05 nM (4)
TK6 human lymphoblastoid cell line/
3 h treatment
0.025 nM
TK6 human lymphoblastoid cell line/
6 h treatment
6.25 nM
TK6 human lymphoblastoid cell line/
24 h continuous treatment
6.25 nM
Methyl methanesulfonate 66-27-3 Alkylatying agent In vitro AHH-1 human lymphoblastoid cell
line
0.8 lg/ml (10)
Ethyl methanesulfonate 62-50-0 Alkylatying agent In vitro AHH-1 human lymphoblastoid cell
line
1.35 lg/ml (10)
In vivo Male Winstar Rats 50 mg/kg (25)
B6C3F1 mice/bone marrow Two times 50 mg/kg (26)
B6C3F1 mice/pheripheral blood Two times 50 mg/kg (26)
CD-1 (IRC) Mice/bone marrow 80 mg/kg/day (27,28)
Acrylamide 79-06-1 Combination of mechanisms In vivo B6C3F1 mice/bone marrow RET 4 mg/kg/day (29)
B6C3F1 mice/bone marrow NCE 6 mg/kg/day (29)
B6C3F1 mice/bone marrow NCE/
haemoglobin adduts as dose metric
1 or 2 mg/kg/day (29)
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may induce defence mechanisms including antioxidant
formation and repair of DNA double-strand break. (30).
After low-dose radiation, growing human fibroblasts could
repair DNA double-strand breaks completely to the level of
unirradiated control (30,31). This may suggest a threshold
type of response curve. In this context, the literature data
presented in 1978 (32) suggest the deviation from linearity in
bone marrow MN test after X-rays exposure (CBA male
mice). However, the non-linear response in MN formation
has been explained by the cell cycle delay induced by
radiation (32). It has been proven using mice bone marrow
MN test that the chronic exposure to low-dose ionising
radiation (0.07 mGy/h) produces the non-linear threshold
response with a threshold located between 35 and 61 cGy of
accumulated irradiation, whereas the acute treatment resulted
in a linear response curve (23).
Topoisomerase II inhibitors. Topoisomerase II is a group of
enzymes that play a crucial role in topographical organisation
of DNA during replication, transcription and DNA repair
processes (8,33,34). Many compounds are known to disrupt
either the catalytic cycle of topoisomerase II (catalytic
inhibitors) or stabilise the topoisomerase II–DNA transient
cleavage complex (topoisomerase II poisons). In contrast to
catalytic inhibitors that disrupt the enzyme physiology,
topoisomerase II poisons by stabilisation of the cleavage
complex may result in fixed DNA double-strand breaks if the
DNA damage is not repaired (8).
In 1995, Record et al. (24) examined the effects of genistein,
genistin and etoposide in mouse splenocytes in vitro. The high
MN level was observed for all tested compounds, however, the
positive effect for genistein started at the third tested
concentration (25 lM) suggesting a thresholded mode of
action (MOA) with a NOEL value at 12.5 lM. In this
perspective, Lynch et al. in 2003 (8) examined the threshold
concept for selected topoisomerase II poisons with different
clastogenic potential and topoisomerase II affinity. Etoposide,
doxorubicin, genistein and ciprofloxacine were tested for MN
induction in L5178Y mouse lymphoma cell line in vitro. Using
mathematical modelling of the experimental data, the threshold
values for etoposide, doxorubicin, genistein and ciprofloxacin
were 0.00236, 0.00151, 1 and 40 lg/ml, respectively. In
contrast, the clastogenicity of genistein has not been confirmed
in vivo in mice and rats (24,35).
Oxidative stress inducers (ROS inducers). Many genotoxi-
cants act through formation of ROS. In physiological state,
ROS are formed constantly as a consequence of metabolic and
biochemical processes. ROS also play a role in signalling
pathways and gene expression (4,36). In the normal
conditions, the amount of ROS is regulated by intracellular
scavengers like vitamin C, glutathione, uric acid or antiox-
idant enzymes like glutathione peroxidase, superoxide
dismutase or catalase. Additionally, mammalian cells possess
very efficient DNA repair systems that limit the ROS-induced
DNA damage. Therefore, actual oxidative stress occurs when
ROS exceeds the amount neutralised by the natural defence
barrier of the organism and causes damage to macromolecules
like proteins, lipids and DNA. Some of the DNA damage,
when not fixed, may lead to mutations (4). Thus compounds
producing ROS are expected to show a NOEL, below which
no statistically significant increase in DNA damage/mutation
(4,36) is seen, as far as the formation of ROS would not
exceed the capacity of the organism to neutralise its harmful
effects.
In 2007, Brink et al. (37) analysed the MN induction in
L5178Y mouse lymphoma cell line after hydrogen peroxide
and cumene hydroperoxide treatment. The response curve after
hydrogen peroxide was reported as supralinear.
In the context of threshold, Platel et al. (4) have investigated
dose-related response in the MN test using human lympho-
blastoid cell line TK6 after treatment with three DNA oxidising
agents: thio-dependent KBrO3, bleomycin (BLM) and hygro-
gen peroxide (H2O2) via glucose oxidase (GOx). For each
compound, three statistically significant plateaus were ob-
served and the highest concentration of the first plateau was
considered as the NOEL. For KBrO3, NOELs were different
dependent on the treatment duration and were 0.9, 0.2 and 5.05
mM for 1-, 2- and 3-h treatment time, respectively. For GOx,
NOEL was 1.8  105 U/ml for 1-h treatment. The BLM
showed 0.05, 0.025 and 6.25 nM values for NOEL at 1, 3 and 6
h, respectively. The shape of the response curve obtained for
short-term treatment with BLM was confirmed by long-term
treatment (with three plateaus), with the NOEL value of 6.25
nM. In contrast, long-term treatment with KBrO3 exhibited
a different concentration–response relationship when compared
to short-term treatment. A two-plateau curve was noted with
a NOEL value of 0.025 mM. For all compounds, the calculated
and the obtained values of NOEL showed a positive correlation
(R2 values ranging from 0.50 to 0.93) (4). It has been
speculated that the first plateau may correspond to the first level
of physiological defence such as scavengers (vitamin C,
vitamin E, GSH and others). By conjugation, they may prevent
from reaction of ROS with DNA, resulting in the NOEL (4).
Mutagens that induce DNA adducts alkylating agents. An
important class of DNA-reactive compounds also used in
chemotherapy is the alkylating agents. The MOA and the DNA
targets have been well characterised and numerous members of
this class of chemicals are either suspected or proven car-
cinogens. Alkylating agents may be classified as mono- or bi-
functional, depending on the number of reactive groups. They
are electrophilic, therefore have high affinity to electron-rich
nucleophilic centres of DNA or proteins. The standard pa-
rameter to characterise the reactivity of alkylating agents is the
Swain Scott constant (s value). Chemicals with high s value target
high nucleophilic centers (e.g. N7-G, N3-A). A low s value
indicates lower sensitivity to nucleophilicity of the target and
therefore the compounds are able to alkylate O atoms (e.g. O6-G)
much more efficiently than compounds with higher s value (10).
In order to scrutinise the type of response curve, Doak et al.
(10) investigated induction of MN in vitro in human
lymphoblastoid cell line AHH-1 after treatment with classical
alkylating agents methylmethane sulfonate (MMS, s value .
0.83), ethylmethane sulfonate (EMS, s value 5 0.67),
methylnitrosourea (MNU, s value 5 0.42) and ethylnitrosourea
(ENU, s value 5 0.26). No clear NOEL was detected for MNU
and ENU. A NOEL value was defined as 0.8 lg/ml for MMS
and 1.35 lg/ml for EMS. Lowest observed effect level (LOEL)
was 0.85 lg/ml for MMS and 1.4 lg/ml for EMS (10). The
different results obtained for MMS versus MNU and EMS
versus ENU may be explained by different mechanisms
involved in DNA repair of alkylated N7-G and O6-G. N7-
alkyl-G adducts are repaired after involvement of base excision
repair (BER) pathway and to lesser extent by mismatch repair,
whereas in the removal of O6-alkyl-G, the methylguanine DNA
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methyltransferase (MGMT) is primarily involved, though
nucleotide excision repair may also be involved when the
MGMT is insufficient. Therefore the non-linear response on
EMS and MMS may be caused by efficient BER and MGMT.
MNU and ENU form far more O6-alkyl-G adducts, which
possibly may not be sufficiently repaired by MGMT.
Additionally, they form O4-alkyl-T and O2-alkyl-T adducts
that are poorly repaired (10,26,27,38,39). Further research
conducted by Brink et al. (37) proved the upward convex
response curve of MN induction when L5178Y cell line was
treated with MMS for 4 h; however, the data did not allow
a conclusion about the potential threshold for concentrations
,50 lM of MMS. A no-threshold response for MNU treatment
has been confirmed in the following studies using several
variants of mouse lymphoma assay, where possible threshold is
suggested for MNU placed in 0.69 lM (40). However, the
threshold dose calculated for MMS and presented by Pottenger
et al. (40) is in a good correlation with the Doak et al. data (10).
A sublinear dose–effect response following EMS treatment
in vivo was published by various groups without defining
a NOEL dose level (41–43). A more recent study performed by
Cammerer et al. (25) estimated a NOEL at 50 mg/kg for
peripheral blood MN induction in male Wistar rats following 2-
day treatment. Sublinear response to EMS treatment was also
presented by Witt et al. (44) when B6C3F1 mice and Fisher
344 rats have been treated on three consecutive days with EMS
(doses 50, 100, 200 and 300 mg/kg/day). The dose of 50 mg/kg
did not show a statistically significant MN induction in bone
marrow and in peripheral blood. In a study by Gocke et al.
(26,27), mice have been treated by oral gavage for 7 days
(EMS: 0, 1.25, 2.5, 5, 20, 80, 140, 200 and 260 and ENU: 0,
1.11, 4.45 and 17.8 mg/kg/day). Doses up to 80 mg/kg/day
showed no increase in bone marrow micronucleated poly-
chromatic erythrocytes, whereas in higher doses, a clear
increase in MN induction was observed. In contrast, the
dose–response curve for ENU treatment did not show any
indication for a threshold. Using mathematical modelling, the
threshold dose for EMS was 89.812 mg/kg/day with
a confidence range between 56.664 and 118.245 mg/kg/day
(26–28,45). However, the EMS threshold has not been
confirmed on the level of protein and DNA adducts formation
(26–28). This may suggest that an error-free DNA repair
system provides successful DNA damage repair resulting in
a lack of fixed mutation up to a threshold dose.
Acrylamide. Many authorities classify acrylamide as a potential
human carcinogen based on its carcinogenicity in rats and
genetic toxicity (29). The metabolic profile of acrylamide has
been well established for humans, rats and mice (29,46). The
primary pathway involves conversion to the reactive epoxide
and glycidamide by cytochrome P450 2E1 (CYP 2E1).
Glycidamide is next metabolised by hydrolases and conjugated
with glutathione. In humans, 15% of acrylamide is converted
to glycidamide, which reacts with DNA and forms N7-G and to
a lesser extend N3-G adducts. In another mechanism, acrylamide
induces oxidative stress in rodents. It may also bind to kinesin
proteins and therefore modify the chromosome segregation and
spindle formation at very low doses though (29).
Hence, Zeiger et al. (29) presented data which evaluated the
shape of mouse bone marrow MN dose–response curve within
the range of low doses. In the study, B6C3F1 mice were treated
for 28 days with 0 (deionised water), 0.125, 0.25, 0.5, 1, 2, 4, 6,
8, 12, 16 and 24 mg/kg/day of acrylamide. One million
normochromatic erythrocytes (NCEs) and .200 000 reticulo-
cytes (RETs) per mouse were scored. NOEL was noted up to 4
and 2 mg/kg/day for MN–RET and MN–NCE, respectively.
MN induction was within these concentrations in the range of
historical control values. Statistical analysis based on adminis-
trated doses and MN–RET or MN–NCE could not discriminate
between linear and non-linear dose–effect relationships. How-
ever, when the regression analysis was based on the glycidamide
haemoglobin adducts as the dose metric, non-linear regression
models fitted the data much better than the linear regression
model. The authors concluded that the acrylamide-based MN
induction showed a threshold dose response (29).
Knowledge gaps and recommendations
For theoretical considerations together with published data, it is
widely accepted that aneugens exhibit a threshold dose–effect
relationship. However, regarding clastogens, the situation is
still challenging and the demonstration of a threshold requires
a clear mechanistic investigation to corroborate experimental
data that stipulate a threshold dose–effect relationship.
Acceptance of a non-linear extrapolation for clastogens will
require exploratory studies to identify the cellular targets and to
scrutinise the different steps from the mutagen–target inter-
actions to MN formation. The situation is even more
demanding when dealing with complex mixtures since the
overall MN frequency may result from different overlapping
but still distinct genotoxic insults (3).
The influence of the genotype on the activation/detoxifica-
tion of genotoxins is well documented and a great variability
between individuals has been observed (reviewed in ref. 47),
therefore the selection of donors should also be taken into
consideration. Experimental design, adequate dose spacing
and the duration of exposure (chronic versus acute) are key
for threshold identification especially for in vivo experiments.
Statistical aspects and appropriate mathematical modelling
should drive threshold estimation. However, based on the
complexity and the variability in the experimental data,
a more elaborated mathematical modelling should be de-
veloped to address the specificities of genotoxicity data taken
into account the sensitivity of the measured end point, i.e. MN
and the statistical power of the assay specially with the
increasing use in the future of automated MN analysis
systems, e.g. image analysis or flow cytometry. The
recognition that a significant number of chemicals operate
by indirect mechanisms of genotoxicity and showing
a possibility of a threshold presents new challenges for the
regulation of chemicals. The regulatory schemes should be
modified to take into account the MOA and possible threshold
effects. When it is demonstrated that a genotoxic substance
has a threshold MOA, the threshold level should be identified
quantitatively. In addition, it has to be assessed whether the
margin of safety between threshold and human exposure is
sufficient for health protection. This assessment should also
take into account variability in the experimental data, the
intra- and inter-species variation, the differences in exposure
and the individual susceptibility.
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